| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08 |
| filingDate |
2013-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4579e34cd9804c733a7463ca28244cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5945f33274bcc56e126e3b8d5a37804
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60574b4e05a320309844952c45da4bf7 |
| publicationDate |
2013-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2013151553-A |
| titleOfInvention |
Use of zoledronic acid for the manufacture of a medicament for the treatment of bone metabolic disorders |
| abstract |
PROBLEM TO BE SOLVED: To administer bisphosphonate to a patient in need of bisphosphonate treatment. The method involves bisphosphonates, particularly 2- (imidazol-1yl) -1-hydroxyethane-1,1-diphosphonic acid (zoledronic acid) or its pharmacology over 15 minutes in a patient in need of the treatment. Relates to a method comprising intravenously administering a pharmaceutically acceptable salt. |
| priorityDate |
2000-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |